

Curriculum Vita



Sep-2025

Personal Background:

First Name: Peyman

Family Name: Eshghi

Place of Birth: Tehran, IR of Iran

Nationality: Iranian

Marital Status: Married

Date of Birth: 30/08/1964

Gender: Male

Work Address:

Mofid Children Hospital, Shariati Aven., Tehran, IRAN, 15468-15514

Work Website /Address:

www.pchd.sbm.u.ac.ir

Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Tel-fax (office) : +98 21 22265488, +98 21 22904536

e-mail : p_eshghi@sbmu.ac.ir

Cc : peshghi64@gmail.com

Educational Background:

1983-1990: MD. , Tehran Medical University

1990-1993: Pediatric specialty, Children Medical Center, Tehran Medical University, Tehran, Iran

1994-1997: Pediatric Hematology & Oncology subspecialty, Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran

Employment and Related Professional Activities, Membership and Affiliation:

Current situation and positions:

- 1) Faculty member of Pediatric Department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran :**
 - Prof. in Pediatric Hematology & Oncology 2012 -now
 - Associate Prof. in Pediatric Hematology & Oncology 2005-2012
- 2) Head attendant of Mofid Comprehensive Care Center for Children with Hemophilia: 2007-now**
- 3) Director of “Pediatric Congenital Hematologic Disorders Research Center” (PCHD): Aug 2023-Now**
 - Deputy of research of PCHD: Aug2012-Aug 2023
- 4) Founder and Chairman of Iranian Society of Thrombosis and Hemostasis (IRSTH) since Jan 2016-Now**
- 5) Founder and Board member of Iranian Pediatric Hematology & Oncology Society (IPHOS) :2000-Now**
- 6) Board Member of Pediatric Hematology & Oncology Sub-specialty discipline in MOH: 2007-Now**
- 7) Member of hematologist counselors Committee in Deputy of health of MOH: 2005-Now**
- 8) Member of Research committee of Iranian Blood Transfusion Organization: 2005-2022**

Previous and other situations and positions:

- 1) **Managing Director of Iranian Blood Transfusion Organization (IBTO): Nov 2019-Feb 2022**
- 2) **President of High Institute for Research and Education in Transfusion Medicine (IRETM) : Nov 2019-Feb 2022**
- 3) Head of pediatric Hematology & Oncology department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran : **May/2011-2019**
- 4) Counsellor to General Director of Iranian Blood Transfusion Organization: **2005-2010**
- 5) Assistant Prof. in pediatric Hematology & Oncology; Ali Asghar Children hospital, Zahedan Medical University, Zahedan, Iran; **1997-2005**
- 6) President of Ali Asghar Children hospital, Zahedan Medical University, Zahedan, Iran: **2000- 2004**
- 7) Head of committee for Establishment of prenatal diagnosis center in Sistan & Balouchestan province(as the 5th national PND center in IRAN) and clinical attendant of this center: **2002-2005**
- 8) Board member of Zahedan Medicine Council Organization: **2004-2006**

Official Appreciations and Awards for Employment and Related Professional Activities:

- 1) **Hemophilia Treatment Centre Twins of the Year Award of WFH in recognition of the exemplary work conducted through Twinning partnership (TEHRAN-MILAN) in 2021.**
- 2) **IRI Medicine Council Organization:**
 - The best Pediatric Hematologist and Oncologist in Iran: in **2005**
- 3) **Ministry of Health and Medical Education for:**
 - Establishment of prenatal diagnosis center in Sistan & Balouchestan province **2005**
 - Diligently cooperation with National Thalassemia Prevention Program; **2008**

- Improvement of Medical documentation in medical education **2000**
- 4) **Zahedan division of IRI Medicine Council Organization:**
 - The best physician in S&B Province: **2001**
- 5) **Zahedan Medical University for:**
 - Establishment of prenatal diagnosis center in Sistan & Balouchestan province **2004**
 - Especial respectability for patients and parents in Ali Asghar Children Hospital **2004**
 - Successful educational efforts and obtaining the first national rank in resident training: **1999**
 - Establishment of Rooming in service for mothers and neonates **1994**
 - The best faculty member. **2001**

Main Investigator or supervisor of National Multicenter Studies and/or National strategic projects in IRAN

- 1- **More than 6 RCT on Iranian Biosimilar and generic strategic medicins and products :**
 - a. **Deferoxamine, deferazirox,rFVIII,rFVIIa (published)**
 - b. **rFVIII-FC , Emicizumab (in process)**
- 2- **Production of AND RCTs on COVID-19 Convalescent Plasma (published)**
- 3- **Eatablishment of the first Children`s Cancer Biobank in Iran (in process)**
- 4- **Establishment of the first Supportive and Palliative Care Center (SPCC) for Children with cancer in IRAN; Mofid Children`s Hospital - 2023 :**
 - a. **Cost-effectiveness cohort study on SPCC for Children with cancer in 2023 (in process)**

International Multicentre Studies (As Main Investigator in IRAN):

- 1- **(3WINTERS-IPS):Type 3 Von Willebrand International Registries Inhibitor Prospective Study - Prospective, Multicentre, International,Non-interventional 5-year Clinical Study .Promoted by AB BONOMI Foundation,a NO-profit Organization with funds obtained from unrestricted grants of Five Companies (published)**
- 2- **Type 3 von Willebrand International Registries Inhibitor Prospective Study (3WINTERS-IPS-EXTENDED), 2020-2022 – Study Code ABB-11-01. Promoted by AB BONOMI Foundation,a NO-profit Organization with funds obtained from unrestricted grants of Five Companies**
- 3- **SIPPET(Survey of Inhibitors in Plasma-Product Exposed Toddlers) Study, and independent ,multicentre, international ,prospective ,controlled ,randomized,open labeled clinical trial.Promoted by Fondazione Angelo Bianchi Bonomi in more than 60 centers around the world (published)**
- 4- **SMART-7: Prospective Observational Study on NovoSeven® RoomTemperature Stable (VII25) in Patients with Haemophilia A or B.an international study. Promoted and sponsored by Novo Nordisk Company (published)**
- 5- **TARGET: study:An observational sTudy to Assess the feasibility of combining data from patient ReGistries in countries with developing health care systems to EvaluaTe Haemophilia management. Promoted and sponsored by Novo Nordisk Company (published)**
- 6- **Patient and Physician Perspectives in the Management of Immune Thrombocytopenia in Iran: Responses from the ITP World Impact Survey (I-WISH). Promoted and sponsored by Novartis Company (published)**
- 7- **Anti-factor VIII inhibitor development upon switching from plasma-derived to recombinant products in patients with haemophilia: An international, multicentre, observational cohort study (PUP-SWITCH), code date: 08.11.2021, STUDY COORDINATOR SITE: Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, U.O.C. (in process)**

Publications:

Book Authorship:

- 1) **Comprehensive Management for congenital bleeding disorders in Iran* 2nd edt.** ,(in Persian) ; IRSTH& MOH publication: 2022
- 2) **Comprehensive Management for Thalassemia in Iran -2nd edt.** ,(in Persian) ; MOH publication: 2018
- 3) **Comprehensive Management for congenital bleeding disorders in Iran* 1st edt.** ,(in Persian) ; MOH publication: 2009
- 4) **Comprehensive Management for Thalassemia in Iran* 1st edt.** ,(in Persian) ; BqUMS& MOH publication: 2005
- 5) **Therapeutic Algorithms Of Musculoskeletal Complications Of Hemophilia,** (in Persian); Nashre Adiban publication: 2010
- 6) **Lymphadenopathy in children** (in Persian): [Pediatric Infectious Disease Research Center, Mofid children Hospital]; Donya-ye Taghzieh publication: 2009
- 7) **Textbook of Pediatrics** (in Persian); Shahid Beheshti University publication: 2005

* *Main Author*

Published Articles in international cited journals:

- 1) Eghbali A, **Eshghi P**, Toogeh G, Alavi S, Badiei Z, Ghanavat M, et al. A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta®(reference product) in previously treated patients with severe haemophilia A. *Annals of Hematology*. 2025;104(2):1195-202.
- 2) **Eshghi P**, Noripour S, Momtazmanesh N, Mojen LK. Development of palliative care for children with cancer in Iran: a local model. *Int J Cancer Manag*. 2025;18(1).
- 3) Ferdowsi S, Mohammadi S, Ahmadnezhad M, Herfat F, Rezvani A, **Eshghi P**, et al. Naturally occurring anti-P1 with high thermal amplitude complicating ABO blood grouping. *Asian Journal of Transfusion Science*. 2024;18(1):135-7.
- 4) Hassan S, Baselli G, Mollica L, Rossi RL, Chand H, El-Beshlawy A, **et al**. Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort. *Blood Advances*. 2024;8(11):2880-9.
- 5) Karbasian F, Nikfarjam M, Noorizadeh K, Abbasi-Kashkooli A, **Eshghi P**, Reihani H. Evaluation of the home safety and child-friendly environment for children with bleeding tendency disorders. *Iranian Journal of Blood and Cancer*. 2024;16(2):51-9.
- 6) Miri S, Rosendaal FR, Kavakli K, **Eshghi P**, Moghaddam SM, Scardo S, et al. Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study. *Research and Practice in Thrombosis and Haemostasis*. 2024;8(8):102595.
- 7) Mohammadi S, Pouladzadeh M, Kouhpayeh H, Okati S, Safdarian M, **Eshghi P**, et al. The effectiveness of convalescent plasma administered on the first day of admission for COVID-19 patients: an open-label randomized controlled trial. *Infectious Diseases & Immunity*. 2024;10.1097.
- 8) Sadr S, Modarresi SZ, **Eshghi P**, Shahkar L, Khalili M, Khoddami M, Rouzbahani AK. Congenital Skin Rashes in an IVF Baby Progressed to Multisystem Langerhans Cell Histiocytosis with Lung and Bone Involvement: A Case Report and Literature Review. *Tanaffos*. 2023 Jan;22(1):176.
- 9) Younesian S, Yousefi AM, **Eshghi P**, Faranoush M, Faranoush P, Keikhaei B, Eghbali A, Shamsian BS, Abdolkarimi B, Haghi S, Abolghasemi H. Genetics and pathophysiology of severe congenital neutropenias (SCNs). *Iranian Journal of Blood and Cancer*. 2023 Jun 30;15(2):146-71.
- 10) **Eshghi P**, Dehghan-Nayeri N. The dispersion of pediatric cancer biobanks in the Middle East: a global review of available resources. *Iranian Journal of Blood and Cancer*. 2023 Jun 30;15(2):113-6.

- 11) Pagliari MT, Budde U, Baronciani L, **Eshghi P**, Ahmadinejad M, Badiie Z, Baghaipour MR, Hidalgo OB, Biguzzi E, Bodó I, Castaman G. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. *Journal of Thrombosis and Haemostasis*. 2023 Apr 1;21(4):787-99.
- 12) Kermani FR, **Eshghi P**, Maghsudlu M, Amini-Kafiabad S, Teimourpour A, Pourkarim MR. Serological Profile of SARS-CoV-2 in Unvaccinated Blood Donors: A Nationwide Study During the Fifth Wave of the Pandemic in Iran. *Jundishapur Journal of Microbiology*. 2023 Mar 31;16(3).
- 13) Kermani FR, Arabkhazaeli A, **Eshghi P**, Maghsudlu M, Amini-Kafiabad S, Teimourpour A, Pourkarim MR. Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic. *Transfusion Clinique et Biologique*. 2023 Feb 1;30(1):123-9.
- 14) Balagholi S, Dabbaghi R, Mohammadi S, Malati ZA, Javan MR, **Eshghi P**. Investigation of the potential of leukoreduction filters in the creation of anti-inflammatory compound. *Transfusion and Apheresis Science*. 2023 Feb 1;62(1):103520.
- 15) Shamsian BS, Jafari MR, Abolghasemi H, **Eshghi P**, Ehsani MA, Shahgholi E, Latifi A, Jamee M. Allogenic Hematopoietic Stem Cell Transplant in Iranian Patients With Congenital Sideroblastic Anemia: A Single-Center Experience. *Experimental and Clinical Transplantation: Official Journal of the Middle East Society for Organ Transplantation*. 2023 Jan 1;21(1):70-5.
- 16) Mohammadi S, Yazdi SM, Balagholi S, Saremi S, Dabbaghi R, Ferdowsi S, **Eshghi P**. Assessment of Standard Operating Procedures (SOPs) Preparing Hygienic Condition in the Blood Donation Centers during the Outbreak of COVID-19. *International Journal of Hematology-Oncology and Stem Cell Research*. 2023 Jul 7;17(3):167.
- 17) Fazeli A, Sharifi S, Behdad F, Okati S, Esmailifar G, Jelveh N, **Eshghi P**, Mohammadi S. Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19. *Transfusion and Apheresis Science*. 2022 Apr 1;61(2):103321.
- 18) Mohammadi S, Aghabozorg F, Balagholi S, Ferdowsi S, Sharifi S, **Eshghi P**. Source Plasma Donation: The Experience of the Iranian Blood Transfusion Organization. *International Journal of Hematology-Oncology and Stem Cell Research*. 2022 Jul 9:151-6.
- 19) Divkolaye N, Arabkhazaeli A, Hajibeigi B, **Eshghi P**. The impact of COVID-19 on blood safety and availability in the Islamic Republic of Iran. *Information for authors*. 2022 1995;1.
- 20) Kermani FR, Arabkhazaeli A, **Eshghi P**, Maghsudlu M, Amini-Kafiabad S, Teimourpour A, Pourkarim MR. Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic. *Transfusion Clinique et Biologique*. 2022 Sep 6.

- 21) Abolghasemi H, Kamfar S, Azarkeivan A, Karimi M, Keikhaei B, Abolghasemi F, Radfar MH, **Eshghi P**, Alavi S. Clinical and genetic characteristics of hemoglobin H disease in Iran. *Pediatric Hematology and oncology*. 2022 Aug 18;39(6):489-99.
- 22) Arabkhazaeli A, Maghsudlu M, Mohammadi S, **Eshghi P**. Positive anti-SARS-CoV-2 rapid serological test results among asymptomatic blood donors. *Transfusion Clinique et Biologique*. 2022 Feb 1;29(1):24-30.
- 23) Fazeli A, Sharifi S, Mohammadi S, Bahraini M, Arabkhazaeli A, Jelveh N, **Eshghi P**. The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection. *Transfusion and Apheresis Science*. 2022 Apr 1;61(2):103302.
- 24) Pagliari MT, Rosendaal FR, Ahmadinejad M, Badiie Z, Baghaipour MR, Baronciani L, Benítez Hidalgo O, Bodó I, Budde U, Castaman G, **Eshghi P**. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study. *Journal of thrombosis and haemostasis*. 2022 May;20(5):1106-14.
- 25) Ferdowsi S, Mohammadi S, Ahmadnezhad M, Herfat F, Rezvani A, **Eshghi P**, Oodi A. Anti-M antibody and ABO blood grouping discrepancy: a report of three cases with review of literature. *Hematology, Transfusion and Cell Therapy*. 2022 Apr;44(2):288.
- 26) Goudarzipour K, Amiri V, **Eshghi P**. Successful Splenectomy Management in a Patient With Moderate Factor VII Deficiency and Concomitant Severe Hereditary Spherocytosis. *Journal of Pediatric Hematology/Oncology*. 2021 Mar 26;43(2):e243-5.
- 27) Abdolkarimi B, Abolghasemi H, Faranoush M, **Eshghi P**, Shamsian S, Shahriari M, Keikhaei B, Momtazmanesh N, Alghasi A, Malek F. Iranian Pediatric Hematology and Oncology Fellowship Curriculum: Updated Version. *Iranian Journal of Blood and Cancer*. 2021 Dec 10;13(4):131-9.
- 28) Alebouyeh M, Aavani P, Abdulrahman NA, Haleem AA, Karimi A, Armin S, Fallah F, Amirali A, Sadr S, Ghandchi G, Abdollahi N.,... **Eshghi P**,... Re-positive PCR of SARS-CoV-2 in health care persons during COVID-19 pandemic. *Cellular and Molecular Biology*. 2021;67(5):138-43.

- 29) Abolghasemi H, Kamfar S, Azarkeivan A, Karimi M, Keikhaei B, Abolghasemi F, Radfar MH, **Eshghi P**, Alavi S. Clinical and genetic characteristics of hemoglobin H disease in Iran. *Pediatric Hematology and Oncology*. 2021 Dec 11:1-1.
- 30) Fazeli A, Sharifi S, Behdad F, Okati S, Esmailifar G, Jelveh N, **Eshghi P**, Mohammadi S. Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19. *Transfusion and Apheresis Science*. 2022 Apr 1;61(2):103321.
- 31) Mehrizi TZ, Kafiabad SA, **Eshghi P**. Effects and treatment applications of polymeric nanoparticles on improving platelets' storage time: a review of the literature from 2010 to 2020. *Blood research*. 2021 Dec 31;56(4):215-28.
- 32) Fathollah Zadeh E, Parry Y, **Eshghi P**. Hope in Iranian mothers of children with cancer: a descriptive correlational study. *Supportive Care in Cancer*. 2021 Jul;29(7):3697-705.
- 33) Pouladzadeh M, Safdarian M, **Eshghi P**, Abolghasemi H, Sheibani B, Choghakabodi PM, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. *Internal and emergency medicine*. 2021:1-11.
- 34) Ahmadnejad M, Mosleh M, Ferdowsi S, Mohammadi S, **Eshghi P**, Oodi A. Cold Agglutinin Associated With COVID-19 Infection in a Thalassemia Patient with Multiple Alloantibodies: A Case of Cold Hemagglutinin Disease (CAD) with Complex Antibody Detection. *Hematology, transfusion and cell therapy*. 2021.
- 35) Arabkhazaeli A, Maghsudlu M, Mohammadi S, **Eshghi P**. Positive anti-SARS-CoV-2 rapid serological test results among asymptomatic blood donors. *Transfusion Clinique et Biologique*. 2021.
- 36) Baronciani L, Peake I, Schneppenheim R, Goodeve A, Ahmadinejad M, Badiee Z, ... **Eshghi P**. et al. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. *Blood advances*. 2021;5(15):2987-3001.
- 37) Hassan S, Palla R, Valsecchi C, Garagiola I, El-Beshlawy A, Elalfy M, **Eshghi P**. et al. Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. *Haemophilia*. 2021.
- 38) Maghsudlu M, **Eshghi P**, Amini Kafi-Abad S, Sedaghat A, Ranjbaran H, Mohammadi S, et al. Blood supply sufficiency and safety management in Iran during the COVID-19 outbreak. *Vox Sanguinis*. 2021;116(2):175-80.
- 39) Mahdavi SA, Fallahinejad Ghajari M, Ansari G, Rezvani Y. , **Eshghi P**. Evaluation of Nasopharynx Bleeding after Nasotracheal Intubation in Dental Patients with Corrected Coagulopathy. *IJBC*. 2021;13(2):40-3.

- 40) Malek F, **Eshghi P**, Mirrahimi B, Alavi S, Nazari S, Shamsian BS, et al. A Prospective Triple-blind Randomized Trial on Safety and Efficacy of Abitant in the Prevention of Chemotherapy-Induced Nausea and Vomiting. *Iranian Journal of Blood and Cancer*. 2021;13(2):35-9.
- 41) Saiyarsarai P, Derakhshan AR, Khedmati J, **Eshghi P**, Seyedifar M. A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis. *Medicine*. 2021;100(40).
- 42) Sarihi R, Ahmadnejad M, Mohammadi S, **Eshghi P**, Herfat F, Jolharnejad S, et al. Hemolytic disease of the fetus and newborn caused by anti-Hr0 in a 27-year-old female with Dc-phenotype: A case report. *Transfusion and Apheresis Science*. 2021;60(1):102913.
- 43) **Eshghi P**, Malek F, Habibpanah B, Davoudabadifarrahani H. Efficacy of Platelet-rich Plasma in the Treatment of Hemophilic Arthropathy [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/efficacy-of-platelet-rich-plasma-in-the-treatment-of-hemophilic-arthropathy/>
- 44) Hassan Abolghasemi , **Peyman Eshghi** , Abdol Majid Cheraghali , *, Abbas Ali Imani Fooladi , Farzaneh Bolouki Moghaddam , Sina Imanizadeh , Matin Moeini Maleki , Mohammad Ranjesh , Mohammad Rezapour , Ali Bahramifar , Behzad Einollahi, Mohammad Javad Hosseini , Nematollah Joneidi Jafari , Mohamad Nikpouraghdami , Nariman Sadri , Mokhtar Tazik, Shanaz Sali , Shamsi Okati , Elham Askari, Payam Tabarsi, Jafar Aslani , Ehsan Sharifipour , Mohammad Hossein Jarahzadeh , Nastaran Khodakarim , Mahmood Salesi , Ramezan Jafarin, Samira Shahverdi. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study . *Transfus Apher Sci*. 2020 Jul 15 : 102875. doi: 10.1016/j.transci.2020.102875 [Epub ahead of print]
- 45) Mahtab Maghsudlu,1 **Peyman Eshghi**,1 Sedigheh Amini Kafi-Abad,1 Abbas Sedaghat,1 Hossein Ranjbaran,1 Saeed Mohammadi1,2 & Seyed Morteza Tabatabai1 Blood supply sufficiency and safety management in Iran during the COVID-19 outbreak (2020) *Vox Sanguini* DOI: 10.1111/vox.13012
- 46) Saeed Mohammadi,1 Seyed Morteza Tabatabaei Yazdi,2, **Peyman Eshghi**3 & Amir Hossein Norooznehad4 Management of COVID-19 Virus Infection by Convalescent Plasma *Vox Sanguinis* (2020) 0, 1–2
- 47) Davood Bashash1*, Hassan Abolghasemi2, Sina Salari3, Meysam Olfatifar4, **Peyman Eshghi**2, Mohammad Esmaeil Akbari5 Elevation of d-dimer, but not pt and aPTT, reflects the progression of covid-19 toward an unfavorable outcome: A meta-analysis (2020) *IJBC* 2020; 12(2): 47-53
- 48) Masoomeh Torkashvand1, Kourosh Goudarzipour1, Mehdi Allahbakhshian Farsani2,3, Vahid Amiri2, Mohammad Hossein Mohammadi2,3, Mozghan Hashemieh4, **Peyman Eshghi**1 Quantitative evaluation of Cerebrospinal fluid (CSF) samples in pediatric patients with low-risk ALL using multiparameter flow cytometry (2020). *Int J Lab Hematol*. 2020;00:1–3.
- 49) Alberto Tosetto 1, Zahra Badiiee 2, Mohammad-Reza Baghaipour 3, Luciano Baronciani 4, Javier Battle 5, Erik Berntorp 6, Imre Bodó 7, Ulrich Budde 8, Giancarlo Castaman 9, Jeroen C.J. Eikenboom 10, **Peyman Eshghi** 11, Cosimo Ettorre 12, Anne Goodeve 13, Jenny Goudemand 14, Charles Richard Morris Hay 15, Hamid Hoorfar 16, Mehran Karimi 17, Bijan Keikhaei 18, Riitta Lassila 19, Frank W.G. Leebeek 20, Maria Fernanda Lopez Fernandez 5, Pier Mannuccio Mannucci 4, Maria Gabriella Mazzucconi 21, Massimo Morfini 9, Johannes Oldenburg 22, Ian Peake 13, Rafael Parra López 23, Flora Peyvandi 4, Reinhard Schneppenheim 24, Andreas Tiede 25, Gholamreza Toogeh 26, Marc Trossaert 27, Omidreza Zekavat 28, Eva M.K. Zetterberg 6 and Augusto B Federici Bleeding symptoms in patients

- diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study (2020). *Journal of Thrombosis and Haemostasis*, Volume 18, Issue 9, September 2020, Pages 2145-2154
- 50) Abdol Majid Cheraghali¹, Hassan Abolghasemi², and **Peyman Eshghi**. Management of COVID-19 Virus Infection by Convalescent Plasma. *Iran J Allergy Asthma Immunol*. May 2020; 19(Suppl.1):3-6.
- 51) **Peyman Eshghi**, S. Zahra Tara, Mohammad Reza Baghaipour, Mohammed Reza Bordbar, Alireza Jenabzade, Behnaz Habibpanah, Nader Cohan, Hakimeh Tavosi, Reza Bahrami, Mehran Karimi. Inhibitors against rFVIIa in patients with severe congenital FVII deficiency: A case series. *Haemophilia*. 2019;00:1–5.
- 52) F. Peyvandi, A. Cannavo, I. G a r a g i o l a , R . P a l l a , P. M. Mannucci, and F. R. rosendaal, A. El-Beshlawy, M. Elalfy, V. Ramanan, Pune, P. Eshghi, S. Hanagavadi, Davangere, R. Varadarajan, M. Karimi, M. V. Manglani, C. Ross, Bangalore, India; G. Young, T. Seth, S. Apte, D. M. Nayak, E. Santagostino, M. Elisa Mancuso, A. C. Sandoval Gonzalez, J. N. Mahlangu, S. Bonanad Boix, M. Cerqueira, N. P. Ewing, C. Male, T. Owaidah, V. Soto Arellano, N. L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakli, M. J. Manco-Johnson, M. Martinez, E. Marzouka, M. G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B. M. Wicklund, B. Zulfikar. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. *Journal of Thrombosis and Haemostasis*, 2018 Jan; 16(1):39-43.
- 53) Nasrin Dehghan-Nayeri, **Peyman Eshghi**, Kourosh Goudarzi Pour, Ahmad Gharehbaghian, A systematic review of proteomic biomarkers associated with risk stratification in pediatric acute lymphoblastic leukemia. *Journal of Paramedical Sciences (JPS) Winter 2018 Vol 9, No1. ISSN 2008-4978*
- 54) K. KAVAKLI, F. DEMARTIS, M. KARIMI, **P. ESHGHI**, D. NEME, H. CHAMBOST, L. SOMMER, M. ZAK and G. BENSON. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. *Haemophilia* (2017), 1-8.
- 55) Francesco Demartis, Angelika Batorova, Hervé Chambost, **Peyman Eshghi**, Mehran Karimi, Kaan Kavakli, Soraya Benchikh El Fegoun, Katarina Cepo, Lene Sommer Vestergaard, Gary Benson. Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses. *TH Open* 2017; 01(02): e130-e138, DOI: 10.1055/s-0037-1608943
- 56) Gholamreza Azizi, Hassan Abolhassani, Seyed Alireza Mahdavian, Zahra Chavoshzadeh, **Peyman Eshghi**, Reza Yazdani, Fatemeh Kiaee, Mohammadreza Shaghghi, Javad Mohammadi, Nima Rezaei, Lennart Hammarström, Asghar Aghamohammadi. Clinical, immunologic, molecular analyses and outcomes of Iranian patients with LRBA deficiency: A longitudinal study. *PAI*, Volume 28, Issue 5, August 2017, Pages 478-484.
- 57) Leila Khanali Mojen, Maryam Rassouli, **1 Peyman Eshghi**, 1 Ali Akbari Sari, 2 and Majideh Heravi Karimooi³. Palliative Care for Children with Cancer in the Middle East: A Comparative Study. *Indian J Palliat Care*. 2017 Oct-Dec; 23(4): 379–386. doi: [10.4103/IJPC.IJPC_69_17]
- 58) Marjan Aghvami†, Ahmad Salimi†, **Peyman Eshghi**, Mohammad H Zarei, Shabnam Farzaneh, Fatemeh Sattari, Afshin Zarghi, Jalal Pourahmad. Targeting the mitochondrial

apoptosis pathway by a newly synthesized COX-2 inhibitor in pediatric ALL lymphocytes. Future Medicinal Chemistry .Published Online: 11 Oct 2018 <https://doi.org/10.4155/fmc-2018-0032>

- 59) Marjan Aghvami, **Peyman Eshghi**, Mohammad Hadi Zarei, Hadi Arefi, Fatemeh Sattarib, Afshin Zarghi and Jalal Pourahmad. Novel Colchicine Analogues Target Mitochondrial PT Pores Using Free Tubulins and Induce ROS-Mediated Apoptosis in Cancerous Lymphocytes. Iranian Journal of Pharmaceutical Research (2018), 17 (4): 1476-1487
- 60) Sezaneh Haghpanah, Tahereh Zarei, **Peyman Eshghi**, Omidreza Zekavat, Mohammadreza Bor dbar, Mahmood Hoormand, Mehran Karimi. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology. October 2018, Volume 97, Issue 10, pp 1919–1924
- 61) Hassan Abolghasemi, MD1, Yunes Panahi, PhD2*, Minoo. Ahmadinejad, MD3, Gholamreza Toogeh, MD4, Mehran Karimi, MD5, Aziz Eghbali, MD6, Nargess Bigom Mirbehbahani, MD7, Bighan Keikhaei Dehdezi, MD8, Zahra Badiee, MD9, Hamid Hoorfar, MD10, **Peyman Eshghi**, MD1, Nader Maghsoudi, PhD11, Amirhossein Sahebkar, PhD12,13,14, Mohammad Gholami-Fesharaki, PhD15. Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. *Journal of Pharmacopuncture* 2018;21[2]:076-081
- 62) Leila Khanali Mojen1 , Maryam Rassouli1 *, **Peyman Eshghi**2 , Kazem Zendedel3 , Ali Akbari Sari4 , Majideh Heravi Karimooi5 , Mamak Tahmasebi3 , Azam Shirin Abadi Farahani1. Pediatric Palliative Care in Iran: Applying Regionalization of Health Care Systems. Asian Pac J Cancer Prev, 19 (5), 1303-1311
- 63) **Peyman Eshghi**1*, Ali Amin Asnafi2, Ahmadreza Shamshiri1, Samin Alavi1, Mohammad Molavi3, Ahmad Tamaddoni4, Bijan Keikhaie2, Majid Naderi5, Hamid Hoorfar6, Shahla Ansari7, Azita Azarkeivan8, Majid Arasteh9, Zahra Kourorian1. The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major. IJBC 2017; 9(3): 2-6
- 64) Kourosh Goudarzipour, Parinaz Alizadeh, Hesameddin Hoseini Tavassol , Reyhaneh Kazemi, **Peyman Eshghi**, Saeed Mojtahedzadeh. A Comparison Between MRIT2 and NT-ProBNP in Early Detection of Heart Diseases in Thalassemia Major Patients: A Cross-Sectional Study. Indian Journal of Hematology and Blood Transfusion. December 2017, Volume 33, Issue 4, pp 541–544
- 65) Karimi M1, **Eshghi P**2, Safarpour MM1, Haghpanah S1, Meshksar A1, Zahedi Z1, Habibpanah B2. Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran. J Pediatr Hematol Oncol. 2018 Jan 19. doi: 10.1097/MPH.0000000000001082. [Epub ahead of print]
- 66) **Peyman Eshghi**, MD1, Elham Sadeghi, MD1, S. Zahra Tara, MD1, Behnaz Habibpanah, BSc1, and Raziieh Hantooshzadeh, MD. Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B. Clinical and Applied Thrombosis/Hemostasis. Clin Appl Thromb Hemost. (2017 Jan) ,1-8. 61:1076029616685429. doi: 10.1177/1076029616685429.
- 67) Nasrin Dehghan-Nayeri , Mostafa Rezaei-Tavirani1 , Mir Davood Omrani , Ahmad Gharehbaghian , Kourosh Goudarzi Pour, **Peyman Eshghi**. Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia. J. Cell Commun. Signal. DOI 10.1007/s12079-016-0357-3

- 68) **Eshghi P**, Amin Asnafi A, Shamshiri A, Alavi S, Molavi M, Tamaddoni A, et al . The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major. *IJBC* 2017; 9 (4) :108-111
- 69) Dehghan-Nayeri N., Gharehbaghian A., Goudarzi Pour K., **Eshghi P**. Over expression of the fatty acid synthase is a strong predictor of poor prognosis and contributes to glucocorticoid resistance in B-cell acute lymphoblastic leukemia. *WCRJ* 2016; 3 (3): e746.
- 70) Goudarzi Pour K, Malek F, **Eshghi P**. Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™). *Case Rep Hematol.* 2016;2016:1295092. doi: 10.1155/2016/1295092. Epub 2016 Jul 10.
- 71) Kouros Goudarzipour MD, **Peyman Eshghi** MD, Zahra Tara MD, Abolfazl Afjeh MD, Farid Solat MD, Masoumeh Shiravi MD. Prevalence of microcytosis in cord blood samples and admitted neonates in Tehran, Iran . *Iran J Ped Hematol Oncol.* 2016, Vol6.No3, 166-171
- 72) Gharibnaseri Z1, Davari M2, Cheraghali A3, **Eshghi P4**, Ravanbod R5, Espandar R6, Hantooshzadeh R7. Health care resource utilization and cost of care for haemophilia A and B patients in Iran. *Transfus Apher Sci.* 2016 Feb;54(1):122-6.
- 73) Faranoush M1, Abolghasemi H2, Mahboudi F3, Toogeh G4, Karimi M5, **Eshghi P6**, Managhchi M4, Hoorfar H7, Dehdezi BK8, Mehrvar A9, Khoeiny B10, Vaziri B3, Kamyar K10, Heshmat R4, Baghaeipour MR11, Mirbehbahani NB12, Fayazfar R13, Ahmadinejad M14, Naderi M15. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor. *Clin Appl Thromb Hemost.* 2016 Mar;22(2):184-90
- 74) Mina Golestania, **Peyman Eshghi**, Abdol Majid Cheraghali*, Hamid Reza Rasekhd, e, Jamshid Salamzadehe, Ali Imani. Cost Components of Treatment Protocols of Haemophilia Patients with Inhibitors using Bypassing Agents in Iran. *Iranian Journal of Pharmaceutical Sciences.* 2016;12 (2): 85-90
- 75) Mina Golestania, **Peyman Eshghi***, Hamid Reza Rasekhd, Abdol Majid Cheraghali, Jamshid Salamzadehc, Majid Naderie, Mohammad Reza Managhchif, Hamid Hoorfarg, Gholam Reza Toogehf, Ali Imanih, Mohammad Taghi Khodayarii, Behnaz Habibpanahb and Razieh Hantooshzadehj. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran. *Iranian Journal of Pharmaceutical Research* (2016), 15 (2): 669-677

- 76) Flora Peyvandi, M.D., Ph.D., Pier M. Mannucci, M.D., Isabella Garagiola, Ph.D., Amal El-Beshlawy, M.D., Mohsen Elalfy, M.D., Vijay Ramanan, M.D., **Peyman Eshghi**, M.D., Suresh Hanagavadi, M.D., Ramabadran Varadarajan, M.D., Mehran Karimi, M.D., Mamta V. Manglani, M.D., Cecil Ross, M.D., Guy Young, M.D., Tulika Seth, M.D., Shashikant Apte, M.D., Dinesh M. Nayak, D.N.B., Elena Santagostino, M.D., Maria Elisa Mancuso, M.D., Adriana C. Sandoval Gonzalez, M.D., Johnny N. Mahlangu, M.Med., Santiago Bonanad Boix, M.D., Monica Cerqueira, M.D., Nadia P. Ewing, M.D., Christoph Male, M.D., Tarek Owaidah, F.R.C.P.A., Veronica Soto Arellano, M.D., Nathan L. Kobrinsky, M.D., Suvankar Majumdar, M.B., Ch.B., Rosario Perez Garrido, M.D., Anupam Sachdeva, M.D., Mindy Simpson, M.D., Mathew Thomas, M.D., Ezio Zanon, M.D., Bulent Antmen, M.D., Kaan Kavakli, M.D., Marilyn J. Manco-Johnson, M.D., Monica Martinez, M.D., Esperanza Marzouka, M.D., Maria G. Mazzucconi, A.P., Daniela Neme, M.D., Angeles Palomo Bravo, M.D., Rogelio Paredes Aguilera, M.D., Alessandra Prezotti, M.D., Klaus Schmitt, M.D., Brian M. Wicklund, M.D., Bulent Zulfikar, M.D., and Frits R. Rosendaal, M.D., Ph.D. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. *N Engl J Med* 2016; 374:2054-2064
- 77) Gholamreza Tooge; Hassan Abolghasemi; **Peyman Eshghi**; Mohammadreza Managhchi; Mohammadreza Shaverdi-niasari; Katayoun Karimi; Samin Roostaei; Neda Emran; Alireza Abdollahi. Evaluation of Aryoseven Safety (recombinant activated factor VII) in patients with bleeding disorders (An observational post-marketing surveillance, study). *IJP Articles in Press*, Accepted Manuscript , Available Online from 11 May 2016
- 78) Gharibnaseri Z1, Davari M2, Cheraghali A3, **Eshghi P4**, Ravanbod R5, Espandar R6, Hantooshzadeh R7. Health care resource utilization and cost of care for haemophilia A and B patients in Iran. *Transfus Apher Sci.* 2016 Feb;54(1):122-6.
- 79) **Peyman Eshghi**, Mohammad Kajiyazdi, Mohammad Hammoud. Recurrent Venous Thromboembolic Events in a Child with Severe Factor X Deficiency. *IJBC* 2016; 8(2): 56-58
- 80) Neda Ashayeri, Elham Sadeghi, Sara Sadeghi, **Peyman Eshghi**, Samin Alavi . Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta-thalassemia Major in Iran; A Non-randomized Controlled Trial. *IJBC* 2016; 8(4): 103-107
- 81) **Eshghi P**, Abolghasemi H, Malek F*, Naderi M, Panahi Y, Habibpanah B, Fatohlahzadeh E, Gorji F. A Prospective Crossover Triple-Blind Controlled Trial on the Safety and Efficacy of Iranian Recombinant FVIII (Safacto®) Versus Plasma Derived FVIII; A Pilot Study. *IJBC* 2015; 7(4): 171-175
- 82) **Eshghi P** , Malek F , Madani F , Esfahani H . Therapeutic Plasma Exchange in Pediatric Severe Immune Thrombocytopenia: A Case Report and Literature Review. *IJBC* 2015; 7(3): 119-122
- 83) Akbar Dorgalaleh, Majid Naderi, Maryam Sadat Hosseini, Shaban Alizadeh, Soudabeh Hosseini, Shadi Tabibian, **Peyman Eshghi**. Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. *Semin Thromb Hemost* 2015; 41(03): 323-329

- 84) Mina Golestani ; **Peyman Eshghi** ; Hamid Reza Rasekh ; Abdol Majid Cheraghali ; Jamshid Salamzadeh ; Ali Imani . Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors. Iran Red Crescent Med J. 2014 December; 16(12): e24551
- 85) Kajbafzadeh AM, Sabetkish S, Turchi A, Amirzadeh N, Afshar K, Abolghasemi H, Elmi A, Talab SS, **Eshghi P**, Mohseni MJ. The application of tissue-engineered preputial matrix and fibrin sealant for urethral reconstruction in rabbit model. Int Urol Nephrol. 2014 Mar 12. [Epub ahead of print]
- 86) Naderi, Dorgalaleh Majid, Tabibian Akbar, Shadi Eshghi, **Eshghi P**, Taregh Alizadeh, Shaban. Association Between Val34Leu Polymorphism and Risk of Umbilical Cord Bleeding in Severe Congenital Coagulation Factor XIII Deficiency in Southeast of Iran. Gene Cell Tissue. 2014; 1(1): e 18360.
- 87) **Eshghi P.**, Jenabzadeh Alireza, Habibpanah Behnaz. Hemorrhage Treatment Report of Patients Suffering from Glanzmann's Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children's Hospital. Iranian Journal of Blood & Cancer. 2014; 6(3); 127-131.
- 88) Naderi Majid, Zarei Tahereh, Haghpanah Sezaneh, **Eshghi P**, Miri-Moghaddam Ebrahim, Karimi Mehran. Intracranial hemorrhage pattern in the patients with factor XIII deficiency. April 2014, Volume 93, Issue 4, pp 693-697
- 89) **Eshghi P** , Jenabzadeh A , Habibpanah B . Hemorrhage Treatment Report of Patients Suffering from Glanzmann's Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children's Hospital. IJBC 2014;6(3): 127-131
- 90) **Eshghi P**, Jenabzade A, Habibpanah B. A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies. Hematology, 2014 Sep;19(6):361-4.
- 91) Naderi M, Dorgalaleh, Tabibian S, Alizadeh Sh, **Eshghi P**, Hosseini S. Effect of Consanguineous Marriages on the High Prevalence of Factor XIII Deficiency in Southeast of Iran. Iranian journal of public health 2013;
- 92) Goudarzi Pour K, **Eshghi P**, Aghakhani R, Askari Reza A, Nejat Mahmud P. Neuroblastoma Associated with Bilateral Ptosis: Report of a Rare Condition. Iranian Journal of Blood and Cancer. 2013; 6(1): 55-57.
- 93) Alavi Samin, Malek Fatima, **Eshghi P**, Arzhangian Hossein. Autologous Platelet-Rich Plasma for Healing of an Oncologic Dehisced Wound. APSP J Case Rep 2013; 4(3):44
- 94) Dorgalaleh A , Naderi M, **Eshghi P**, Tabibian shadi. Clinical manifestations of rare bleeding disorders in South East of Iran Hemophilia. 2013; 19(2):PO 382
- 95) Naderi M, Dorgalaleh A, Tabibian Sh, Alizadeh Sh, **Eshghi P**, Solaimani G. Current understanding in diagnosis and management of factor XIII deficiency. Iran J Ped Hematol Oncol. 2013;3(4):164-72.

- 96) Ziaee Seyyed Amir Mohsen, Reza Sarhangnejad, Hassan Abolghasemi, **Eshghi P**, Mohammad Hadi Radfar, Ali Ahanian, Mehdi Kardoust Parizi, Nasser Amirzadeh, Akbar Nouralizadeh. Autologous fibrin sealant in tubeless percutaneous nephrolithotomy; a prospective study *Urology journal* (impact factor: 0.58). 01/2013; 10(3):999-1003.
- 97) Alzoebie A, Belhani M, **Eshghi P**, Kupesiz AO, Ozelo M, Pompa MT, Potgieter J, Smith M. Establishing a harmonized haemophilia registry for countries with developing health care systems. *Haemophilia*. 2013 Apr 17. doi: 10.1111/hae.12147. Epub 2013 Apr 17
- 98) Naderi M, **Eshghi P**, Cohan N, Haghpanah S, Karimi M. Evaluation of the FXIII deficiency prophylaxis intervals in large number of FXIII deficiency patients from Iran. *Haemophilia*. 2013 Mar 19. doi: 10.1111/hae.12112. [Epub ahead of print]
- 99) Alizadeh Z, Fazlollahi MR, Houshmand M, Maddah M, Chavoshzadeh Z, Hamidieh AA, Shamsian BS, **Eshghi P**, Bolandghamat Pour S, Sadaaie Jahromi H, Mansouri M, Movahedi M, Nayebpour M, Pourpak Z, Moin M. Different pattern of gene mutations in Iranian patients with severe congenital neutropenia (including 2 new mutations). *Iran J Allergy Asthma Immunol*. 2013 Mar;12(1):86-92. doi: 012.01/ijaai.869213.
- 100) **Eshghi P**, Khanali L, Abed-Saeedi J, Farahani H, Abdollah Gorgi F, Habib-Panah B, Tehrani Tarighat S, Alavi S, Taslimi S. The effect of on demand and prophylactic therapeutic methods on quality of life among hemophilic children. *IJBC* 2013;2: 57-60
- 101) **Peyman Eshghi**, Nader Cohan, Majid Naderi, Mehran Karimi. Factor XIII deficiency: a review of literature. *IJBC* 2012;2: 85-91
- 102) Salehi Tahmineh, Fazlollahi Mohammad Reza, Maddah Marzieh, Nayebpour Mohsen, Tabatabaei, Yazdi, Mojtaba Alizadeh, Zahra, **Eshghi P**, Chavoshzadeh Zahra Movahedi, Masoud Hamidieh, Amirali Cheraghi, Taher Pourpak, Zahra Moin, Mostafa. Prevention and Control Of Infections In Patients With Severe Congenital Neutropenia; A Follow Up Study. *Iranian Journal Of Allergy, Asthma And Immunology (Ijaai)*. 2012; 11(1): 51-56.
- 103) Naderi M **Eshghi P**, Saneei Moghaddam E, Alizadeh S, Dorgalaleh A, Younesi MR, Khateb ZK. Safety of human blood products in rare bleeding disorders in southeast of Iran. *Haemophilia*. 2012 Dec 6. doi: 10.1111/hae.12068. [Epub ahead of print]
- 104) K. Salem, **Eshghi P**. Dental health and oral health-related quality of life in children with congenital bleeding disorders. *Haemophilia* (2012), 1–6
- 105) Naderi M, **Eshghi P**, Cohan N, Miri-Moghaddam E, Yaghmaee M, Karimi M. Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of 17 cases in Iran. *Haemophilia*. 2012 Sep;18(5):773-776. Epub 2012 Mar 28.
- 106) Cheraghali Abdol Majid, **Eshghi P**. Cost Assessment of Implementation of Immune Tolerance Induction in Iran. *Value in Health Regional Issues*. 1 (2 0 1 2) 5 4 – 5 8
- 107) M. Karimi, A. Vafafar, S. Haghpanah, M. payandeh, **Eshghi P**, H. Hoofar, A. Afrasiabi, J. Gerdabi, R. Ardeshiri, M. Menegatti– and F. Peyvandi. Efficacy of prophylaxis and genotype-

- phenotype correlation in patients with severe Factor X deficiency in Iran. *Haemophilia* (2012), 18, 211–215
- 108) **Eshghi P**, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, Karimi M. Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran *Clin Appl Thromb Hemost*. 2011 Dec 6. [Epub ahead of print]
- 109) Alizadeh Z, Fazlollahi MR, **Eshghi P**, Hamidieh AA, Ghadami M, Pourpak Z. Iran Two Cases of Syndromic Neutropenia with a Report of Novel Mutation in G6PC3. *J Allergy Asthma Immunol*. 2011 Sep;10(3):227-30
- 110) **Eshghi P**, Farahmandinia Z. , Molavi M., Naderi M. , Jafroodi M. , Hoorfar H., Davari K., Azarkeivan A. , Keikhaie B. , Ansari S. , Arasteh M. : Efficacy and safety of Iranian made Deferasirox (osveral®) in Iranian major Thalassemic Patients with transfusional iron overload :A One year Prospective Multicentric Open-Label Non-Comparative study. *Daru*, 2011, Vol. 19, No.3, 240-248
- 111) A.M. Cheraghali, **Eshghi P.**, H. Abolghasemi .Social consequences of infected haemophilia cases in the Islamic Republic of Iran. *EMHJ*, 2011, Vol. 17 ,No. 6 ,.552-556
- 112) Miri-Moghaddam E., Zadeh-Vakili A., Rouhani Z., Naderi M., **Eshghi P.**, Khazaei A. Feizabad6. Molecular basis and prenatal diagnosis of β -thalassemia among Balouch population in Iran. *Prenat Diagn* (2011)
- 113) Alireza Foroutan, Fariba Beigzadeh, Mohammad Jafar Ghaempanah, **Eshghi P**, Naser Amirizadeh, PhD, Hamed Sianati, MD, Pooria Foroutan, MD. Efficacy of Autologous Fibrin Glue for Primary Pterygium Surgery with Conjunctival Autograft. *Iranian Journal of Ophthalmology* 2011;23(1):39-47
- 114) **Eshghi P**. Moradveisi B. Frequency of Decreased Bone Mineral Density and Its Risk Factors during Childhood among Iranian Hemophilia Patients. *Iranian Journal Of Blood And Cancer* 2011;4(1):
- 115) **Peyman Eshghi**, Kourosh Goudarzipour, Hoorieh Davoudabadi Farahani, Roxana Aghakhani Intra articular Injection of Rifampin in Iranian Children with Hemophilic Arthropathy. *Iranian Journal of Blood and Cancer*, Volume 3, Number 2. Winter 2011
- 116) Kajbafzadeh AM, Abolghasemi H, **Eshghi P**, Alizadeh F, Elmi A, Shafaattalab S, Dianat S, Amirizadeh N, Mohseni MJ. Single-donor fibrin sealant for repair of urethrocutaneous fistulae following multiple hypospadias and epispadias repairs. *J Pediatr Urol*. 2010 Jul 14. [Epub ahead of print]
- 117) Eghbali Aziz, **Eshghi P**, Malek F, Abdollahpour Hengameh., Rezaei Nima. HAX1 mutation in an infant with severe congenital neutropenia. *The Turkish Journal of Pediatrics* 2010; 52: 81-84
- 118) **Eshghi P**, Mitra Mahdavi-Mazdeh, Mehran Karimi, Mohammad Aghighi. Haemophilia in the developing countries: the Iranian experience. *Arch Med Sci* 2010; 6, 1: 83-89

- 119) **Eshghi P**, Mahjour SB, Naderi M, Dehbozorgian J, Karimi M. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. *Haemophilia*. 2010 Mar;16(2):383-5.
- 120) Aziz Eghbali, MD; **Peyman Eshghi**, MD; Fatemeh Malek, MD and Nima Rezaei, MD, PhD. Cardiac and Renal Malformations in a Patient with Sepsis and Severe Congenital Neutropenia. *Iran J Pediatr*, Vol 20 (No 2); Junr 2010
- 121) Zadeh-Vakili A, **Eshghi P** Detection of a rare mutation in an Iranian family: codons 37/38/39 (7 bp deletion). *Hemoglobin*. 2009;33(6):523-7.
- 122) **Peyman Eshghi** , Kourosh Goudarzi Pour and Roxana Aghakhani. Methyltetrahydrofolate Reductase C677T Mutation and 4G/5G Plasminogen Activator Inhibitor-1 Polymorphism in a Child with Deep Vein Thrombosis. *Iranian Journal of Blood and Cancer*, Volume 1, Number 4 (2009)
- 123) **Peyman Eshghi**, Hassan Abolghasemi. Selection Bias in reporting the prevalence of Transfusion Transmitted Infection Diseases in Iranian Hemophiliacs. *Iranian Journal of Pathology*(2009)4 (4).197-198
- 124) **Eshghi P**, Rashidi A, Zadeh-Vakili A, Miri-Moghadam E. Hematological phenotype of the IVS-I-5 (G > C) beta-thalassemia mutation and assessment of Iran's national screening criteria. *Hemoglobin*. 2008;32(5):440-5.
- 125) **Eshghi P.**, Zadeh-Vakili A, Rashidi A, Miri-Moghadam E. An unusually frequent beta-thalassemia mutation in an Iranian Province. *Hemoglobin*. 2008;32(4):387-92.
- 126) Trinh CH, Sh Elsayed W, **Eshghi P**, Miri-Moghaddam E, Zadeh-Vakili A, Markham AF, Anwar R. Molecular analysis of sixteen unrelated factor XIII A deficient families from south-east of Iran. *Br J Haematol*. 2008 Mar;140(5):581-4.
- 127) A. Zadeh-Vakili, **P. Eshghi**, Gh. Rastegar Lari. Efficiency of BclI Restriction Fragment Length Polymorphism for Detection of Hemophilia A Carriers in Sistan and Baluchestan Province, Southeast of Iran. *Iran J Med Sci March* 2008; Vol 33 No 1 33
- 128) Sharifi-Mood B, **Eshghi P**, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. *Saudi Med J*. 2007 Oct;28(10):1516-9.
- 129) Abolghasemi H, Amid A, Zeinali S, Radfar MH, **Eshghi P**, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H. Thalassemia in Iran: epidemiology, prevention, and management. *J Pediatr Hematol Oncol*. 2007 Apr;29(4):233-8
- 130) **Eshghi P**, Alavi S, Ghavami S, Rashidi A.. Growth impairment in beta-thalassemia major: the role of trace element deficiency and other potential factors. *J Pediatr Hematol Oncol*. 2007 Jan;29(1):5-8.

- 131) Ashena Zahra, Alavi Samin, Arzanian Mohammad Taghi., **Eshghi P**, Nail involvement in Langerhans cell Histiocytosis, *Pediatric Hematology and Oncology*, 24:45–51, 2007
- 132) **P. Eshghi**. Complications of Combined Treatment with Deferiprone and Desferrioxamine in Thalassemic Patients, *Iran J Med Sci*, 2007; 32(1)
- 133) Sharifi-Mood B, Smail Sanei-Moghaddam, Salehi M, **Eshghi P**, Soheila Khosravi and Manijeh Khalili. Viral Infection among Patients with Hemophilia in the Southeast of Iran, *Journal of Medical Sciences* 2006; 6(2): 225-228,
- 134) Karimi M. **Eshghi P.**, Unusual Lymphoblastic Leukemia/Lymphoma in Eastern Iran ,*Indian Journal of Pediatrics*, 2006; 73
- 135) **Eshghi P**, Abolghasemi Hassan, Esmail Sanei-Moghaddam, , Anwar Rashida, Jazebi Mohammad , Amid Ali, Fereydoun A. Ala, MD, FRCP, FRCPath ,, Factor XIII deficiency in southeast Iran, *Haemophilia* (2004), 10, 470–472

Published Articles in Iranian Journals (in Persian) :

- 1) Arzanian M.T., Shamsian B.Sh., Eshghi P., Kajiyazdi M., Alavi S., Nazari Sh., Goudarzipour K. The clinical application of port A Cath in the hematology-oncology patients *Sci J Iran Blood Transfus Organ* 2015; 12(1): 85-99
- 2) Factor XIII deficiency in Sistan and Baluchistan province. Naderi M, Imani M, Alizadeh Sh, Dorgalaleh A, Tabibian Sh, **Eshghi P**, Sanei Moghaddam E, Mirimoghaddam E, *Journal of Iranian Blood transfusion Organization Research Center* 01/2013
- 3) Miri-Moghaddam E., Eshghi P., Sanei Moghaddam E., Hashemi SM. Prevalence of hemoglobinopathies in Sistan and Balouchistan province in the southeast of Iran. *Sci J Iran Blood Transfus Organ* 2013; 9(4): 406-413
- 4) Azarkeivan A, Arjangyan MH, Hajibeigi B, Afradi H, Aghaeepour M, Razjoo F, Sharifi SH, **Eshghi P**. Evaluation and Comparison of Washed RBCs by Closed and Open systems. *Scientific Journal of Zanjan University*; 1390; 19(75):66-76.
- 5) **Eshghi P**, Amin Asnafi A. Cerebral venous thrombosis in a child with Acute Lymphoblastic Leukemia and G20210A mutation of prothrombin gene during treatment. *Sci J Iran Blood Transfus Org.* 2011; 8(2): 143-148

- 6) Zahedpanah M, Azarkeivan A, Hajibeigi B, Ahmadinezhad M, **Eshghi P**, Tabatabaiee M.R. 1, Maghsudlu M. Coagulation inhibitors in Thalassemia. *Sci J Iran Blood Transfus Org.* 2010; 7(2): 78-84
- 7) Eshghi P.1,2(MD), Cheraghali A.M.1,3(PhD); Legal, social, and economic consequences of transfusion transmitted infections in Iran and in the world. **The Scientific Journal of Iranian Blood Transfusion Organization Research Center. Volume 6, Number 4 (Spring 2009)**
- 8) Noori N, **Eshghi P**, Shahramian I. Evaluation the effectiveness of combined iron chelation with deferipron and desferoxamine on the cardiac function in major beta thalassemic children in Zahedan,1383-1384. *Tabib-e Shargh.* Winter 88.No.11,Vol4.:35-40
- 9) Hashemi Teir A.1(MS), Amirizadeh N.1(PhD), **Eshghi P.**, Abolghasemi H.1,3(MD),Amani M.1(MS), Jabari A.1(BS), Ranjbaran R.1(MS), Mohammadi M.H.1(MS),Habibi Roudkenar M.1(PhD), Ali Balazadeh A. **Study of *in vitro* properties of fibrin sealant prepare from single donor plasma** 4(*BS. Sci J Iran Blood Transfus Org* 2009; 6(3): 181-189
- 10) Noori N, **Eshghi P**. Evaluation the effectiveness of captopril on the left heart function in major beta thalassemic children in Zahedan, 1381-1382. *Scientific Medical Journal.* Winter 2008; 6(4 (55)):492-498.
- 11) Shahriari HA, MD; Ghasemzadeh F, MD; **P. Eshghi**, MD; Masoomian B, MD. **Ocular Side Effects of Desferal □ in Patients with □Thalassemia.** *Bina J Ophthalmol* 2006; 11 (4): 519-523
- 12) **Eshghi Peyman**, Aliakbarian M, Taheribojd M.A, Davoudabadi H.**Classification of Arthropathies in Severe hemophilia type A, referred to Zahedan in 2003.** *Medical Journal Of Mashad University of Medical Sciences*, No.91, Vol49, Spring 2006
- 13) Abolghsemi H, **Eshghi Peyman**, Rahiminejad M.S, Hatami S. Evaluation and Cost-Effectiveness Analysis Of Prevention Program Of **Major Thalassemic in in Sistan and Baluchestan province** and Fars Province, *HAKIM* Winter. 2006; 8():85-14.
- 14) **Eshghi Peyman**, Rahimi M, Razaghi A;**Evaluation of effect of Family practice Consultation on Knowledge, Attitude and Practice of Major Thalassemic`s**

Parents in the Prevention Program in Southeast IRAN, Scientific Medical Journal of Ahwaz University of Medical Science , No.49 , Vol5, No2, Summer 2006.

- 15) **Eshghi Peyman MD** , Abolghasemi H. MD. , Sanei moghadam E. MD. , et al. , **Prevalence of factor XIII deficiency and abnormal clot solubility test in Sistan and Baluchestan province**, Hakim Research Journal , Vol.6 ,No.4 , Winter 2004
- 16) **Eshghi Peyman MD**, Razlansari Ali Akbar MD. , Roodbari Masood PHD . , **Prevalence of Impaired Oral Glucose Tolerance Test in Major Thalassemic Patients with and without Hepatitis C Virus Infection in Zahedan in 2001**, Scientific Medical Journal of Ahwaz University of Medical Science , No.38 ,December 2003.
- 17) **Eshghi Peyman MD.** , Sanei moghadam E. MD., Mirmasoudi M. MD, **Evaluation of Alloimmunization in major B.thalassemic patients in zahedan in 2001**, Journal of Mazandaran University of Medical Sciences , Vol.13 No.40 , Autumn 2003.
- 18) Miri-Moghadam E., Naroinejad.Mehrnaz , **Eshghi Peyman**, et al. **Molecular basis and Prenatal diagnosis of thalassemia in southeast Iran** . Journal Of Mazandaran University OF Medical Sciences, Fall 2003; 13():36-42.

Performance summary : (https://isid.research.ac.ir/Peyman_Eshghi)

Scopus articles

H index: 21

G index: 39

Citation : 1,834 (Citations by 1,607 documents)

Published in Journals (by IF) : Q1 : 15% ; Q2 : 30 % ; Q3 :35 % ; Q4 : 18%


First-Author Papers: 21 Corresponding-Author Papers: 15 International Papers:15

Papers with at least 10 citation: 35%

Self-Citation: 4%

Papers in Citescore Top 10% Journals : 10%

[Paper International Collaborations Web of Science\(ISI\)](#)



Updated at 23-04-2024

J. Estaji